Programmed cell death 1 (PD-1) is expressed on activated T cells, B cells, monocytes, and macrophages (97), the interaction of PD-L1 with its receptor PD-1 inhibits T-cell responses, and a blockade of this interaction has been proven to be an effective immunotherapy for several different cancers (98). Here, CD274 is linked to cancer.